PANC-1 pancreatic cancer cell line (PANC-1)

PANC-1 is a human pancreatic cancer cell line derived from a 56-year-old male with pancreatic ductal adenocarcinoma (PDAC) originating in the head of the pancreas. In the context of drug discovery, PANC-1 is not a specific molecular target (such as a receptor or enzyme) but rather a complex biological model used to study the behavior of pancreatic cancer cells and their response to potential therapeutic agents. The cell line is characterized by its epithelioid morphology, its ability to grow in soft agar (indicating anchorage-independent growth), and its chromosomal abnormalities typical of aggressive malignancy. Genetic analysis of PANC-1 reveals critical mutations common in PDAC, including a G12D mutation in the KRAS oncogene and mutations in the TP53 tumor suppressor gene, which drive its high proliferative and invasive capacity. Because it represents a complete cellular system, researchers use PANC-1 to investigate various signaling pathways, metabolic reprogramming, and mechanisms of resistance to standard treatments like gemcitabine. (Sources: American Type Culture Collection (ATCC) [https://www.atcc.org/products/crl-1469]; National Center for Biotechnology Information (NCBI) [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401290/]).

Other names

PANC1Panc-1 human pancreatic cancer cellsPancreatic epithelioid carcinoma cell line

Not applicable as PANC-1 is a multi-molecular cell line model, not a specific drug target molecule.